Research uncovers cells-of-origin for breast cancer in BRCA2 mutation carriers

NewsGuard 100/100 Score

Australian scientists have pinpointed likely 'cells-of-origin', the source cells that can grow into breast cancer, in women carrying a faulty BRCA2 gene who are at high risk of developing the disease.

The WEHI-led study also showed these cells have potential to be targeted with an existing cancer drug to delay tumor growth, in findings that may lead to future preventive treatments for the disease.

At a glance

  • Women with faulty BRCA2 genes are at a substantially higher risk of developing breast cancer, with 70% of carriers going on to develop the disease, which is often aggressive.

  • A milestone finding from a WEHI-led research study has pinpointed likely 'cells-of-origin' that have the potential to develop into breast cancers in women carrying a faulty BRCA2 gene.

  • The scientists also uncovered a vulnerability in these cells that they successfully targeted with an existing cancer drug to delay tumour growth in the lab.

Abnormal cells

Women who inherit and carry a faulty BRCA2 gene have a substantially increased risk of developing breast cancer – approximately 70% of carriers will develop the disease over their lifetime.

These cancers often occur at a young age and can be clinically aggressive. Early screening is encouraged and some women undertake preventive breast surgery (mastectomy) to reduce their breast cancer risk.

In a milestone finding published in Nature Cell Biology, researchers have discovered the likely 'cells-of-origin' of cancer in BRCA2 carriers. By comparing cancer-free tissue samples from both carriers and non-carriers, they identified an aberrant population of cells that divide more quickly.

Study joint first author Dr Rachel Joyce said this perturbed cell population was found in the majority of tissue samples from women with a faulty BRCA2 gene.

Given they were found in most of the BRCA2 tissue samples from healthy females, we believe these may be the cells-of-origin that lead to future breast cancers in women that carry the BRCA2 mutation."

Dr Rachel Joyce, study joint first author

Treatment targets

The aberrant cells in BRCA2 tissue, a subset of breast ductal cells called luminal progenitor cells, stood out to the scientific team because they displayed altered protein production, which is critical for the correct growth and functioning of tissues in our bodies.

"These changes may also make the cells more vulnerable to certain therapies aimed at preventing or delaying breast cancer development," said study joint first author Dr Rosa Pascual.

Lead author Professor Jane Visvader said the team developed a pre-clinical BRCA2 model that showed similar alterations in the ductal cells, and targeted them with the existing cancer drug everolimus, which is approved to treat patients with relapsed breast cancer.

"Through pinpointing this vulnerability in protein production, we were able to show that pre-treatment with this drug delayed the formation of tumours in the pre-clinical model," said Prof Visvader, joint head of the ACRF Cancer Biology and Stem Cells Division and the Breast Cancer Laboratory at WEHI.

"This raises the possibility that targeting specific aspects of protein production in this way could represent a new breast cancer prevention strategy for women with a faulty BRCA2 gene."

Towards prevention

The findings are an important first step towards the goal of preventative treatments for breast cancer in BRCA2-mutation carriers.

Study author and cancer clinician, Professor Geoff Lindeman said that while the findings were exciting, more work was needed before they could be applied in the clinic.

"While everolimus did delay tumour development in the lab, this drug can have side-effects, which might limit its capacity to be used as a preventative treatment," said Prof Lindeman, joint head of the ACRF Cancer Biology and Stem Cells Division at WEHI, and a medical oncologist at the Royal Melbourne Hospital and Peter MacCallum Cancer Centre.

"Our team want to further explore which specific parts of protein processing are dysregulated, and use this information to develop more selective and tolerable preventative treatments.

"There's still a way to go, but we're a big step closer.

"A few years ago, we identified the likely cells-of-origin for breast cancer in females carrying a fault in the BRCA1 gene, which is also associated with a high risk of developing breast cancer. That research has since led to an international breast cancer prevention study (BRCA-P).

"We hope that our new findings will now inform future treatment and prevention for women with a faulty BRCA2 gene."

The study, 'Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriers', is published in Nature Cell Biology (DOI: 10.1038/s41556-023-01315-5).

The research was carried out on breast tissue samples kindly donated by women undergoing breast surgery, with assistance from the Victorian Cancer Biobank (funded by the Victorian Government) and the Kathleen Cuningham Foundation Consortium for research into Familial Breast cancer. The research was supported by the National Health and Medical Research Council, Breast Cancer Research Foundation, the National Breast Cancer Foundation, The Medical Research Future Fund, the Two Sisters Foundation and the Heine Family.

Source:
Journal reference:

Joyce, R., et al. (2024). Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriers. Nature Cell Biology. doi.org/10.1038/s41556-023-01315-5.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals vascular health disparities between Black and white men with prostate cancer diagnosis